Dr. Rudolph M. Navari, MD

Dr. Navari practices at Hematology and Oncology Associates of Alabama in Gadsden, Alabama.

Dr. Navari's NPI, 1891778023, was assigned on November 22, 2005. Dr. Navari holds Alabama license 8424.

Dr. Navari's primary practice is Hematology and Oncology Associates of Alabama, at 705 Goodyear Ave, Gadsden, AL 35903 in Etowah County. The practice phone is (256) 492-0375.

Dr. Navari's primary practice is Hematology and Oncology Associates of Alabama in Gadsden, Alabama. Dr. Navari is also affiliated with Gadsden Regional Medical Center. The medical group on file is UAB Medicine. Dmand AI also links Dr. Navari to 6 more medical groups and 3 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Navari practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Navari's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Navari is licensed in Alabama.

CMS data shows 557 Medicare services from Dr. Navari across 10 procedure codes in 2024, for 130 Medicare patients. Medicare paid $13,067 for them.

CMS counts 130 Medicare patients who saw Dr. Navari in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 14% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Navari's median patient age at 68, with 54% women.

In 2024, Dr. Navari wrote 281 Medicare Part D claims for 109 patients. 86% of them were for generic drugs. CMS names the drug for 156 of them, across 7 drugs with 11 or more claims each, at $10,546 in total drug cost. In 2023, CMS named 971 claims across 30 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Navari for performance year 2024, reported as part of a group. Dr. Navari accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Navari as offering telehealth.

Dmand AI links 58 papers to Dr. Navari, published from 2005 to 2025. 2016 was the busiest year, with 5. The most frequent topics are Nausea, Vomiting and Antiemetics. Dr. Navari has published most often in Support Care Cancer. Dr. Navari's most frequent co-authors are Lee S. Schwartzberg, MD, Eric Roeland, MD and Charles L. Loprinzi, MD.

Dmand AI links Dr. Navari to 2 clinical trials. Conditions studied include Vomiting and Signs and Symptoms, Digestive.

CMS Open Payments shows 195 general payments to Dr. Navari from 28 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 86% of the total. Heron Therapeutics, Inc. paid the most, $280,227. It also lists 1 research payment totaling $300 in 2022.